AstraZeneca Partner Daiichi Sankyo Says Breast Cancer Drug Demonstrates Improvements in Primary Endpoints in Phase 3 Trial-February 2024-www.financetom.com

AstraZeneca Partner Daiichi Sankyo Says Breast Cancer Drug Demonstrates Improvements in Primary Endpoints in Phase 3 Trial

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

AstraZeneca Partner Daiichi Sankyo Says Breast Cancer Drug Demonstrates Improvements in Primary Endpoints in Phase 3 Trial

Oct 6, 2025 1:38 AM

04:14 AM EDT, 10/06/2025 (MT Newswires) -- AstraZeneca ( AZN ) and Daiichi Sankyo said Monday that their breast cancer drug Datroway demonstrated statistically significant and clinically meaningful improvement in the primary endpoints of overall survival and progression-free survival compared with chemotherapy in a phase 3 trial.

Datroway had a safety profile consistent with previous trials in the same disease, they said.

The drug was discovered by Daiichi Sankyo and is being jointly developed and commercialized with AstraZeneca ( AZN ).

Previous page： Second-hand shopping a $1-billion-plus business for Amazon in Europe Next page： CNBC-TV18 Newsbreak Confirmed: Aster DM Health arm to sell Aster DM Healthcare FZC stake to Alpha GCC for $1.01 billion

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.